170 related articles for article (PubMed ID: 37632009)
1. Phenothiazines Inhibit SARS-CoV-2 Entry through Targeting Spike Protein.
Liang T; Xiao S; Wu Z; Lv X; Liu S; Hu M; Li G; Li P; Ma X
Viruses; 2023 Jul; 15(8):. PubMed ID: 37632009
[TBL] [Abstract][Full Text] [Related]
2. Phenothiazines inhibit SARS-CoV-2 cell entry via a blockade of spike protein binding to neuropilin-1.
Hashizume M; Takashima A; Ono C; Okamoto T; Iwasaki M
Antiviral Res; 2023 Jan; 209():105481. PubMed ID: 36481388
[TBL] [Abstract][Full Text] [Related]
3. High-throughput drug screening allowed identification of entry inhibitors specifically targeting different routes of SARS-CoV-2 Delta and Omicron/BA.1.
Kuzikov M; Woens J; Zaliani A; Hambach J; Eden T; Fehse B; Ellinger B; Riecken K
Biomed Pharmacother; 2022 Jul; 151():113104. PubMed ID: 35643072
[TBL] [Abstract][Full Text] [Related]
4. Sertraline Is an Effective SARS-CoV-2 Entry Inhibitor Targeting the Spike Protein.
Chen Y; Wu Y; Chen S; Zhan Q; Wu D; Yang C; He X; Qiu M; Zhang N; Li Z; Guo Y; Wen M; Lu L; Ma C; Guo J; Xu W; Li X; Li L; Jiang S; Pan X; Liu S; Tan S
J Virol; 2022 Dec; 96(24):e0124522. PubMed ID: 36468859
[TBL] [Abstract][Full Text] [Related]
5. Structural Study of SARS-CoV-2 Antibodies Identifies a Broad-Spectrum Antibody That Neutralizes the Omicron Variant by Disassembling the Spike Trimer.
Zhan W; Tian X; Zhang X; Xing S; Song W; Liu Q; Hao A; Hu Y; Zhang M; Ying T; Chen Z; Lan F; Sun L
J Virol; 2022 Aug; 96(16):e0048022. PubMed ID: 35924918
[TBL] [Abstract][Full Text] [Related]
6. The Integral Membrane Protein ZMPSTE24 Protects Cells from SARS-CoV-2 Spike-Mediated Pseudovirus Infection and Syncytia Formation.
Shilagardi K; Spear ED; Abraham R; Griffin DE; Michaelis S
mBio; 2022 Oct; 13(5):e0254322. PubMed ID: 36197088
[TBL] [Abstract][Full Text] [Related]
7. Inhibition of SARS-CoV-2 (previously 2019-nCoV) infection by a highly potent pan-coronavirus fusion inhibitor targeting its spike protein that harbors a high capacity to mediate membrane fusion.
Xia S; Liu M; Wang C; Xu W; Lan Q; Feng S; Qi F; Bao L; Du L; Liu S; Qin C; Sun F; Shi Z; Zhu Y; Jiang S; Lu L
Cell Res; 2020 Apr; 30(4):343-355. PubMed ID: 32231345
[TBL] [Abstract][Full Text] [Related]
8. Discovery and Evaluation of Entry Inhibitors for SARS-CoV-2 and Its Emerging Variants.
Acharya A; Pandey K; Thurman M; Klug E; Trivedi J; Sharma K; Lorson CL; Singh K; Byrareddy SN
J Virol; 2021 Nov; 95(24):e0143721. PubMed ID: 34550770
[TBL] [Abstract][Full Text] [Related]
9. Targeting the Fusion Process of SARS-CoV-2 Infection by Small Molecule Inhibitors.
Park SB; Irvin P; Hu Z; Khan M; Hu X; Zeng Q; Chen C; Xu M; Leek M; Zang R; Case JB; Zheng W; Ding S; Liang TJ
mBio; 2022 Feb; 13(1):e0323821. PubMed ID: 35012356
[TBL] [Abstract][Full Text] [Related]
10. Emergence and Re-emergence of Human Coronaviruses: Spike Protein as the Potential Molecular Switch and Pharmaceutical Target.
Ahmad F; Kamal MA; Tekwani BL
Curr Pharm Des; 2021; 27(33):3566-3576. PubMed ID: 33327904
[TBL] [Abstract][Full Text] [Related]
11. Identification of broad, potent antibodies to functionally constrained regions of SARS-CoV-2 spike following a breakthrough infection.
Guenthoer J; Lilly M; Starr TN; Dadonaite B; Lovendahl KN; Croft JT; Stoddard CI; Chohan V; Ding S; Ruiz F; Kopp MS; Finzi A; Bloom JD; Chu HY; Lee KK; Overbaugh J
Proc Natl Acad Sci U S A; 2023 Jun; 120(23):e2220948120. PubMed ID: 37253011
[TBL] [Abstract][Full Text] [Related]
12. Monoclonal antibodies constructed from COVID-19 convalescent memory B cells exhibit potent binding activity to MERS-CoV spike S2 subunit and other human coronaviruses.
Peng Y; Liu Y; Hu Y; Chang F; Wu Q; Yang J; Chen J; Teng S; Zhang J; He R; Wei Y; Bostina M; Luo T; Liu W; Qu X; Li YP
Front Immunol; 2022; 13():1056272. PubMed ID: 36618428
[TBL] [Abstract][Full Text] [Related]
13. The use of Pseudotyped Coronaviruses for the Screening of Entry Inhibitors: Green Tea Extract Inhibits the Entry of SARS-CoV-1, MERSCoV, and SARS-CoV-2 by Blocking Receptor-spike Interaction.
Joseph J; Karthika T; Das VRA; Raj VS
Curr Pharm Biotechnol; 2022; 23(8):1118-1129. PubMed ID: 34375189
[TBL] [Abstract][Full Text] [Related]
14. A novel cyclic γ-AApeptide-based long-acting pan-coronavirus fusion inhibitor with potential oral bioavailability by targeting two sites in spike protein.
Xue S; Wang X; Wang L; Xu W; Xia S; Sun L; Wang S; Shen N; Yang Z; Huang B; Li S; Cao C; Calcul L; Sun X; Lu L; Cai J; Jiang S
Cell Discov; 2022 Sep; 8(1):88. PubMed ID: 36075899
[TBL] [Abstract][Full Text] [Related]
15. Cross-Neutralization of Emerging SARS-CoV-2 Variants of Concern by Antibodies Targeting Distinct Epitopes on Spike.
Changrob S; Fu Y; Guthmiller JJ; Halfmann PJ; Li L; Stamper CT; Dugan HL; Accola M; Rehrauer W; Zheng NY; Huang M; Wang J; Erickson SA; Utset HA; Graves HM; Amanat F; Sather DN; Krammer F; Kawaoka Y; Wilson PC
mBio; 2021 Dec; 12(6):e0297521. PubMed ID: 34781736
[TBL] [Abstract][Full Text] [Related]
16. Abiotic Synthetic Antibody Inhibitor with Broad-Spectrum Neutralization and Antiviral Efficacy against Escaping SARS-CoV-2 Variants.
Li B; Zhao Y; Wu X; Wu H; Tang W; Yu X; Mou J; Tan W; Jin M; Li W; Zhang Q; Liu M
ACS Nano; 2023 Apr; 17(7):7017-7034. PubMed ID: 36971310
[TBL] [Abstract][Full Text] [Related]
17. Effective Inhibition of SARS-CoV-2 Entry by Heparin and Enoxaparin Derivatives.
Tandon R; Sharp JS; Zhang F; Pomin VH; Ashpole NM; Mitra D; McCandless MG; Jin W; Liu H; Sharma P; Linhardt RJ
J Virol; 2021 Jan; 95(3):. PubMed ID: 33173010
[TBL] [Abstract][Full Text] [Related]
18. A Palmitic Acid-Conjugated, Peptide-Based pan-CoV Fusion Inhibitor Potently Inhibits Infection of SARS-CoV-2 Omicron and Other Variants of Concern.
Lan Q; Chan JF; Xu W; Wang L; Jiao F; Zhang G; Pu J; Zhou J; Xia S; Lu L; Yuen KY; Jiang S; Wang Q
Viruses; 2022 Mar; 14(3):. PubMed ID: 35336956
[TBL] [Abstract][Full Text] [Related]
19. Ganoderma microsporum immunomodulatory protein acts as a multifunctional broad-spectrum antiviral against SARS-CoV-2 by interfering virus binding to the host cells and spike-mediated cell fusion.
Ho HPT; Vo DNK; Lin TY; Hung JN; Chiu YH; Tsai MH
Biomed Pharmacother; 2022 Nov; 155():113766. PubMed ID: 36271550
[TBL] [Abstract][Full Text] [Related]
20. A Five-Helix-Based SARS-CoV-2 Fusion Inhibitor Targeting Heptad Repeat 2 Domain against SARS-CoV-2 and Its Variants of Concern.
Xing L; Xu X; Xu W; Liu Z; Shen X; Zhou J; Xu L; Pu J; Yang C; Huang Y; Lu L; Jiang S; Liu S
Viruses; 2022 Mar; 14(3):. PubMed ID: 35337003
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
